The whole set of trials this year across the pipeline were designed with the attention and recommendations from BP. That's what the CDA's are all about.
Soon we see the fruits of their labor and our patience.
Soon. Off to a great start for 2018. I can see a MAJOR trial for kevetrin in our future, marketing and phase 3 for brilacidin and prurisol.